Pierrepont Therapeutics, a Pittsburgh, PA-based company focusing on treatments for primary mitochondrial and rare diseases, raised $500K in funding.
The Mito Fund made the investment.
The company intends to use the funds to expand operations and its R&D sector.
Pierrepont Therapeutics is dedicated to developing targeted treatments for primary mitochondrial and other rare genetic diseases. Its lead product candidate, PTI-501 (formerly ENTR-501) is a proprietary intracellular enzyme replacement therapy for the treatment of MNGIE that is exclusively licensed from Entrada Therapeutics, Inc. (Nasdaq: TRDA). The founders of Pierrepont, including Daniel DiPietro, have expertise and success in mitochondrial disease drug development, and have relationships with KOLS, families, and patient advocacy groups in the mitochondrial disease community.
FinSMEs
07/04/2024